Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT
Piera Angelillo,Ana Alarcon Tomas,Edoardo Campodonico,Urban Novak,Ludovic Gabellier,Igor Wolfgang Blau,Mi Kwon,Ron Ram,Edouard Forcade,Caroline Besley,Vladan Vucinic,Nicolaus Kröger,Lucía López Corral,Jan Vydra,Silvia Ferrari,Bastian von Tresckow,Marie Therese Rubio,Rafael Hernani,Simona Sica,Friedrich Stölzel,Montserrat Rovira,Eva Wagner-Drouet,Jose Antonio Pérez-Simón,Cristina Castilla-Llorente,Andres J. M. Ferreri,Jorinde D. Hoogenboom,Isabel Sanchez Ortega,Florent Malard,Jürgen Kuball,Annalisa Ruggeri
DOI: https://doi.org/10.1038/s41409-024-02451-8
2024-10-26
Bone Marrow Transplantation
Abstract:Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1]. As of 2024, the European Medicine Agency (EMA) has approved four CAR T-cell products for the treatment of B-cell lymphomas, either diffuse (DLBCL), high-grade (HGBCL), follicular lymphoma (FL), primary mediastinal (PMBCL) or mantle cell lymphoma (MCL): tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and brexucabtagene autoleucel (brexu-cel) [2,3,4,5]. Although reference centers are building an increasingly robust experience concerning CAR T-cell administration, acute inflammatory complications, namely cytokine release syndrome (CRS) and immune-effector cell associated neurotoxicity syndrome (ICANS), still pose considerable threats to recipients, restricting access to treatment over fear of unacceptable toxicity or jeopardizing outcomes due to the need for intensive care measures [6, 7]. ICANS is an incompletely understood encephalopathy syndrome manifested through a constellation of clinical symptoms that might be variably present early after CAR T-cell administration, spanning from mild tremor, confusion and aphasia to deep coma and status epilepticus [8]. Due to the paucity of robust data, at the time of this writing, the treatment algorithm in ICANS is mostly based on expert opinion and includes high-dose corticosteroids and anti-interleukins such as anakinra, as well as supportive care [9]. No consensus exists as to the use of prophylactic anti-epileptic drugs, either on a universal basis or upon the development of initial neurologic symptoms. In particular, several centers still administer routine levetiracetam prophylaxis in compliance with international guidelines, although data in support of this practice remain scarce [10].
oncology,immunology,hematology,transplantation